Aduro BioTech, Inc. has entered into its second agreement with Janssen Biotech, Inc., granting an exclusive, worldwide license to certain product candidates for the treatment of lung cancer and certain other cancers, based on its LADD immunotherapy platform.
 
Aduro will receive $30 million upfront and is eligible to receive development, regulatory and commercialization milestones potentially totaling $817 million. Aduro is also eligible to receive royalties on worldwide sales upon commercialization.
 
Janssen will have exclusive rights to develop and commercialize LADD product candidates in lung cancer and will assume responsibility for all R&D, manufacturing, regulatory and commercialization activities for the licensed products. Aduro may provide assistance in any of these areas upon request for additional fees.
 
“Since our initial agreement with Janssen in May of this year for new immunotherapies for prostate cancer, they have been terrific partners and we’ve established a strong collaboration focused on advancing our technologies forward in their licensed indications,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “We believe our LADD technology also offers tremendous promise as a potential treatment for lung cancer and we are pleased to expand our relationship with Janssen, a company with significant experience and resources focused in both lung and prostate cancer.”